ClinicalTrials.gg
Active, not recruitingNCT04908202Updated Oct 16, 2026Results posted

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

A Phase 3 interventional study of Deucravacitinib and Placebo in Psoriatic Arthritis, sponsored by Bristol-Myers Squibb. Active, not recruiting at 183 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Updated Oct 16, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
670
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb — 1 open to participants now, 3 under way, 3 of them phase 3. Arthritis, Psoriatic · Bristol-Myers Squibb.

Started
2021
with 1 other
Phase 3
4 of 12
1 open now
Registered
8th of 12
by date

Among the 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb, this one is one of 2 that started in 2021, is one of 4 in phase 3, and was the 8th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

1 of the 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb is open now. Recruiting first, the newest first:

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis who are naïve to biologic disease-modifying anti-rheumatic drugs. The long term extension period will provide additional long-term efficacy and safety information.

03

Conditions studied

  • Psoriatic Arthritis

Keywords

  • Biologic-Naive
  • BMS-986165
  • Deucravacitinib
  • Disease-modifying Anti-rheumatic Drugs
  • DMARDs
  • Joint Disease
  • Psoriatic Arthritis
  • PsA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed to have psoriatic arthritis (PsA) of at least 3 months duration at screening.
  • Meets the Classification Criteria for Psoriatic Arthritis at Screening.
  • Active plaque psoriatic skin lesion(s) or documented medical history of plaque psoriasis (PsO) at screening.
  • Active arthritis as shown by ≥ 3 swollen joints and ≥ 3 tender joints at Screening and day 1.
  • Participant has high sensitivity C-reactive protein (hsCRP) ≥ 3 mg/L at Screening.
  • ≥ 1 PsA-related hand and/or foot joint erosion on X-ray during Screening Period that is confirmed by central reading.
  • Must have completed the week 52 treatment for the optional open-label long-term extension period.

Exclusion criteria

Exclusion Criteria

  • Nonplaque psoriasis at screening or day 1.
  • Other condition such as systemic lupus erythematous, mixed connective tissue disease, multiple sclerosis, or vasculitis.
  • History of or current inflammatory joint disease other than PsA (e.g., gout, reactive arthritis, rheumatoid arthritis, ankylosing spondylitis, Lyme disease).
  • Active fibromyalgia.
  • Received an approved or biologic therapy for the treatment of PsA or PsO.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
670 participants (actual)

Study arms

  • Experimental
    Deucravacitinib

    Drug: Deucravacitinib

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • Specified dose on specified days

    Also known as: BMS-986165

  • OtherPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With ACR 20 Response at Week 16

    The ACR 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 20% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication. The 95% CI is calculated using Clopper-Pearson exact method.

    Time frame: Week 16

Secondary outcomes

  1. Change From Baseline in Disease Activity Score 28 C-reactive Protein (DAS28-CRP) at Week 16

    DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: \< 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; \>5.1=high disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAS28-CRP indicates an improvement.

    Time frame: Baseline and Week 16

  2. Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 16

    HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in HAQ-DI indicates an improvement.

    Time frame: Baseline and Week 16

  3. Percentage of Participants Meeting Psoriatic Area and Severity Index (PASI) 75 Response at Week 16, in Participants With at Least 3% Body Surface Area (BSA) Involvement and at Least Static Physician's Global Assessment (sPGA) 2 at Baseline

    PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value. The 95% CI is calculated using Clopper-Pearson exact method.

    Time frame: Week 16

  4. Change From Baseline in the 36-item Short Form (SF-36) Physical Subcomponent Summary (PCS) Score at Week 16

    SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The physical subcomponent summary (PCS) consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The scores range from 0 to 100, with a higher score indicating better quality of life. The PCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 PCS indicates an improvement.

    Time frame: Baseline and Week 16

  5. Percentage of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Leeds Enthesitis Index (LEI) at Week 16

    Percentage of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by Leeds Enthesitis Index (LEI). An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 enthesial sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden.

    Time frame: Week 16

  6. Percentage of Participants Meeting Achievement of Minimal Disease Activity (MDA) at Week 16

    Percentage of participants meeting achievement of MDA where an MDA response is achievement of 5 of 7 following outcomes at Week 16: 1. Tender joint count \<= 1 2. Swollen joint count \<=1 3. Psoriasis Area and Severity Index (PASI) \<= 1 or body surface area (BSA) \<= 3% 4. Patient assessment of psoriatic arthiritis (PsA) pain \<= 15 5. Patient Global Assessment of PsA disease activity \<= 20 6. HAQ-DI \<= 0.5 7. Tender enthesial points \<= 1

    Time frame: Week 16

  7. Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score at Week 16

    FACIT-Fatigue evaluates a range of self-reported symptoms over the past week, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience or symptoms of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The recall period is 7 days. Each item is rated on a 5-point Likert scale ranging from 0 = "not at all" to 4 = "very much." Sum scores for the 13 items range from 0 through 52, where higher scores indicate less fatigue. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in FACIT-Fatigue indicates an improvement.

    Time frame: Baseline and Week 16

  8. Percentage of Participants Meeting Dactylitis Resolution at Week 16

    Percentage of participants meeting dactylitis resolution at Week 16 among the participants with dactylitis at baseline, where resolution is defined as a tender dactylitis count of 0 in participants with a tender dactylitis count =\> 1 at baseline. The number of digits in hands and feet with dactylitis will be counted by a blinded assessor.

    Time frame: Week 16

  9. Change From Baseline in PsA-modified Sharp-van Der Heijde (SvdH) Score at Week 16

    The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage. Change from baseline reflects progression or improvement; a decrease suggests reduced damage or improvement.

    Time frame: Baseline and Week 16

  10. Percentage of Participants With ACR 20 Response up to Week 16

    The ACR 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 20% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication. The 95% CI is calculated using Clopper-Pearson exact method.

    Time frame: Week 2, 4, 8, 12, and 16

  11. Percentage of Participants With ACR 50 Response up to Week 16

    The ACR 50 definition of improvement is a 50% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 50% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication. The 95% CI is calculated using Clopper-Pearson exact method.

    Time frame: Week 2, 4, 8, 12, and 16

  12. Percentage of Participants With ACR 70 Response up to Week 16

    The ACR 70 definition of improvement is a 70% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 70% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication. The 95% CI is calculated using Clopper-Pearson exact method.

    Time frame: Week 2, 4, 8, 12, and 16

  13. Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) up to Week 16

    HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in HAQ-DI indicates an improvement.

    Time frame: Baseline and Week 2, 4, 8, 12, and 16

  14. Percentage of Participants Who Achieve a Clinically Meaningful Improvement in Health Assessment Questionnaire - Disability Index (HAQ-DI) up to Week 16 Among Participants With a HAQ-DI Score ≥0.35 at Baseline

    HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered. Clinically meaningful improvement was defined as ≥0.35improvement from baseline.

    Time frame: Baseline and Week 2, 4, 8, 12, and 16

  15. Percentage of Participants Meeting Psoriatic Area and Severity Index (PASI) 75 Response up to Week 16, in Participants With at Least 3% Body Surface Area (BSA) Involvement and at Least Static Physician's Global Assessment (sPGA) 2 at Baseline

    PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value. The 95% CI is calculated using Clopper-Pearson exact method.

    Time frame: Week 4, 8, 12 and 16

  16. Percentage of Participants Meeting Psoriatic Area and Severity Index (PASI) 90 Response up to Week 16, in Participants With at Least 3% Body Surface Area (BSA) Involvement and at Least Static Physician's Global Assessment (sPGA) 2 at Baseline

    PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 90 is the number of participants who experience at least a 90% improvement in PASI score as compared with the baseline value. The 95% CI is calculated using Clopper-Pearson exact method.

    Time frame: Week 4, 8, 12 and 16

  17. Percentage of Participants Meeting Psoriatic Area and Severity Index (PASI) 100 Response up to Week 16, in Participants With at Least 3% Body Surface Area (BSA) Involvement and at Least Static Physician's Global Assessment (sPGA) 2 at Baseline

    PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 100 is the number of participants who experience at least a 100% improvement in PASI score as compared with the baseline value. The 95% CI is calculated using Clopper-Pearson exact method.

    Time frame: Week 4, 8, 12 and 16

  18. Change From Baseline in the 36-item Short Form (SF-36) Physical Subcomponent Summary (PCS) Score up to Week 16

    SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The physical subcomponent summary (PCS) consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The scores range from 0 to 100, with a higher score indicating poor quality of life. The PCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 PCS indicates an improvement.

    Time frame: Baseline and Week 4, 12 and 16

  19. Percentage of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Leeds Enthesitis Index (LEI) up to Week 16

    Percentage of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by Leeds Enthesitis Index (LEI). An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 enthesial sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden.

    Time frame: Week 4, 8, 12 and 16

  20. Percentage of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Spondyloarthritis Research Consortium of Canada (SPARCC) up to Week 16

    Percentage of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by SPARCC. The SPARCC Enthesitis Index has a 0 to 16 score that is derived from the evaluation of 8 locations: the greater trochanter (right \\\[R\\\]/left \\\[L\\\]), quadriceps tendon insertion into the patella (R/L), patellar ligament insertion into the patella and tibial tuberosity (R/L), Achilles tendon insertion (R/L), plantar fascia insertion (R/L), medial and lateral epicondyles (R/L), and supraspinatus insertion (R/L). A higher count indicates a higher enthesitis burden based on the current evaluation.

    Time frame: Week 4, 8, 12 and 16

  21. Percentage of Participants Meeting Achievement of Minimal Disease Activity (MDA) up to Week 16

    Percentage of participants meeting achievement of MDA where an MDA response is achievement of 5 of 7 following outcomes at Week 16: 1. Tender joint count \<= 1 2. Swollen joint count \<=1 3. Psoriasis Area and Severity Index (PASI) \<= 1 or body surface area (BSA) \<= 3% 4. Patient assessment of psoriatic arthiritis (PsA) pain \<= 15 5. Patient Global Assessment of PsA disease activity \<= 20 6. HAQ-DI \<= 0.5 7. Tender enthesial points \<= 1

    Time frame: Week 4, 8, 12, and 16

  22. Change From Baseline in the 36-item Short Form (SF-36) Mental Component Summary (MCS) Score up to Week 16

    SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The mental component summary (MCS) of the SF-36 consists of these 4 subscales: Vitality, Social functioning, Role-emotional, Mental health. The scores range from 0 to 100, with a higher score indicating poor quality of life. The MCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 MCS indicates an improvement.

    Time frame: Baseline and Week 4, 12 and 16

  23. Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score up to Week 16

    FACIT-Fatigue evaluates a range of self-reported symptoms over the past week, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience or symptoms of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The recall period is 7 days. Each item is rated on a 5-point Likert scale ranging from 0 = "not at all" to 4 = "very much." Sum scores for the 13 items range from 0 through 52, where higher scores indicate less fatigue. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in FACIT-Fatigue indicates an improvement.

    Time frame: Baseline and Week 2, 4, 8, 12 and 16

  24. Percentage of Participants Meeting Dactylitis Resolution up to Week 16

    Percentage of participants meeting dactylitis resolution at Week 16 among the participants with dactylitis at baseline, where resolution is defined as a tender dactylitis count of 0 in participants with a tender dactylitis count =\> 1 at baseline. The number of digits in hands and feet with dactylitis will be counted by a blinded assessor.

    Time frame: Week 4, 8, 12 and 16

  25. Change From Baseline in Psoriatic Arthritis Impact of Disease (PsAID) 12 Score up to Week 16

    The Psoriatic Arthritis Impact of Disease (PsAID) is a 12-item self-report that measures PsA symptoms and impact of disease. Each item is scored on a 0 to 10 numeric rating scale with a 1-week recall period. The PsAID has a total score, with a higher value indicating worse health. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in PsAID indicates an improvement.

    Time frame: Baseline and Week 2, 4, 8, 12 and 16

  26. Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) Score up to Week 16

    The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \\\[cm\\\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. The DAPSA score ranges from 0 to 154, with a higher score indicating more disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAPSA indicates an improvement.

    Time frame: Baseline and Week 2, 4, 8, 12 and 16

  27. Percentage of Participants With Achievement of Disease Activity Index for Psoriatic Arthritis (DAPSA) Low Disease Activity Response up to Week 16

    The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \\\[cm\\\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. A higher DAPSA score indicated more active disease activity.

    Time frame: Baseline and Week 2, 4, 8, 12 and 16

  28. Percentage of Participants With Achievement of Disease Activity Index for Psoriatic Arthritis (DAPSA) Disease Remission up to Week 16

    The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \\\[cm\\\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. A higher DAPSA score indicated more active disease activity. A score 0 signifies remission.

    Time frame: Baseline and Week 2, 4, 8, 12 and 16

  29. Percentage of Participants Meeting Achievement of Physician Global Assessment-Fingernails (PGA-F) of 0/1 up to Week 16

    The PGA-F is a 5-point scale used to assess fingernails separately for nail bed signs and nail matrix signs of disease. A global score of between 0 indicating clear, and 4 indicating severe. The overall condition of the fingernails is rated on a 5-point scale: 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, and 4 = severe.

    Time frame: Week 2, 4, 8, 12 and 16

  30. Change From Baseline in Disease Activity Score 28 C-reactive Protein (DAS28-CRP) up to Week 16

    DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: \\\< 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; \\\>5.1=high disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAS28-CRP indicates an improvement.

    Time frame: Baseline and Week 2, 4, 8, 12 and 16

  31. Percentage of Participants Meeting Disease Activity Score 28 C-reactive Protein (DAS28-CRP) Low Disease Activity Response up to Week 16

    DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: \\\< 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; \\\>5.1=high disease activity.

    Time frame: Week 2, 4, 8, 12 and 16

  32. Percentage of Participants Meeting Disease Activity Score 28 C-reactive Protein (DAS28-CRP) Disease Remission up to Week 16

    DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: \\\< 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; \\\>5.1=high disease activity.

    Time frame: Week 2, 4, 8, 12 and 16

  33. Change From Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS) up to Week 16

    The Psoriatic Arthritis Disease Activity Score (PASDAS) is a composite measure calculated from the Physician Global Assessment of PsA, the Participant Global Assessment of Disease Activity, the Short Form-36 PCS, the swollen joint count, the tender joint count, the Enthesitis (LEI), the Dactylitis (LDI) (Basic), and the High-sensitivity C-reactive protein (hsCRP). The range of PASDAS is 0-10. Higher score means more active disease. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.

    Time frame: Baseline and Week 4, 12 and 16

  34. Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) up to Week 16

    Four domains are used to calculate the modified Composite Psoriatic Disease Activity Index (mCPDAI): joints (66 swollen joint count and 68 tender joint count; Health Assessment Questionnaire), skin (PASI and DLQI), dactylitis (a simple count of each digit involved), and enthesitis (number of tendons/fascia insertion sites showing enthesitis scored from 0 to 4, based on palpation of Achilles tendon and bilateral plantar fasciae insertion). The mCPDAI is scored using a 4 point scale from 0 (no disease activity) to 3 (most severe disease activity), giving an mCPDAI score range of 0 through 12. A higher score indicates more active disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.

    Time frame: Baseline and Week 4, 8, 12 and 16

  35. Percentage of Participants With Achievement of Psoriatic Arthritis Response Criteria (PsARC) up to Week 16

    The Psoriatic Arthritis Response Criteria (PsARC) consists of 4 measurements: tender joint count, swollen joint count, Physician Global Assessment of PsA, and Participant Global Assessment of Disease Activity. In order to be classified as a PsARC responder, participants must achieve improvement in 2 of 4 measures, 1 of which must be joint pain or swelling, without worsening in any measure. Improvement in each of the measures is defined below: 1) Decrease of ≥ 30% in tender joint counts; 2) Decrease of ≥ 30% in swollen joint counts; 3) Decrease of ≥ 20% in Physician Global Assessment of PsA; 4) Decrease of ≥ 20% in Participant's Global Assessment of Disease Activity

    Time frame: Week 2, 4, 8, 12 and 16

  36. Percentage of Participants Meeting Achievement of Improvement of Bath Ankylosing Spondylitis Disease Activity (BASDAI) Score up to Week 16

    BASDAI consists of a 0 to 10 scale measuring discomfort, pain, and fatigue in response to 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: 1) Fatigue (medical); 2) Spinal pain; 3) Joint pain and swelling; 4) Areas of localized tenderness; 5) Morning stiffness duration; 6) Morning stiffness severity. A higher count indicates worse disease. Each individual question response is scaled to a 0-10 score by dividing by 10, and the BASDAI is derived using the following formula: BASDAI = ((Q1 + Q2 + Q3 + Q4) + ((Q5 + Q6) / 2)) / 5

    Time frame: Week 2, 4, 8, 12 and 16

  37. Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Scores Response of <= 0 at Week 16

    The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.

    Time frame: Week 16

  38. Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Scores Response of <= 0.5 at Week 16

    The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.

    Time frame: Week 16

  39. Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Scores Response of <= Smallest Detectable Change (SDC) at Week 16

    The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage. SDC is calculated as 1.96\* standard deviation of the paired differences of change from baseline/ square root of (2\*k); k is the number of reviewers and is default to 2 in this study.

    Time frame: Week 16

  40. Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Erosion Scores Response of <= 0 at Week 16

    The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.

    Time frame: Week 16

  41. Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Erosion Scores Response of <= 0.5 at Week 16

    The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.

    Time frame: Week 16

  42. Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Erosion Scores Response of <= SDC at Week 16

    The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage. SDC is calculated as 1.96\* standard deviation of the paired differences of change from baseline/ square root of (2\*k); k is the number of reviewers and is default to 2 in this study.

    Time frame: Week 16

  43. Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Joint Space Narrowing (JSN) Scores Response of <= 0 at Week 16

    The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.

    Time frame: Week 16

  44. Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Joint Space Narrowing (JSN) Scores Response of <= 0.5 at Week 16

    The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.

    Time frame: Week 16

  45. Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Joint Space Narrowing (JSN) Scores Response of <= SDC at Week 16

    The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage. SDC is calculated as 1.96\* standard deviation of the paired differences of change from baseline/ square root of (2\*k); k is the number of reviewers and is default to 2 in this study.

    Time frame: Week 16

  46. Change From Baseline in PsA-modified SvdH Erosion Scores Response at Week 16

    The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.

    Time frame: Baseline and Week 16

  47. Change From Baseline in PsA-modified SvdH JSN Scores Response at Week 16

    The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.

    Time frame: Baseline and Week 16

  48. Change From Baseline in the 36-item Short Form (SF-36) Physical Subcomponent Summary Score up to Week 16

    SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The physical sub component is one of the 4 subscales of PCS. The physical subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 physical sub-component indicates an improvement.

    Time frame: Baseline and Week 4, 12 and 16

  49. Change From Baseline in the 36-item Short Form (SF-36) Role Activity Subcomponent Summary Score up to Week 16

    SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The role activity sub component is one of the 4 subscales of PCS. The role activity subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 role activity indicates an improvement.

    Time frame: Baseline and Week 4, 12 and 16

  50. Change From Baseline in the 36-item Short Form (SF-36) Bodily Pain Subcomponent Summary Score up to Week 16

    SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The bodily pain sub component is one of the 4 subscales of PCS. The bodily pain subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 bodily pain subcomponent indicates an improvement.

    Time frame: Baseline and Week 4, 12 and 16

  51. Change From Baseline in the 36-item Short Form (SF-36) General Health Perceptions Subcomponent Summary Score up to Week 16

    SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The general health perceptions sub component is one of the 4 subscales of PCS. The general health perceptions subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 general health perceptions subcomponent indicates an improvement.

    Time frame: Baseline and Week 4, 12 and 16

  52. Change From Baseline in the 36-item Short Form (SF-36) Vitality Subcomponent Score up to Week 16

    SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The vitality subcomponent is one of the 4 subscales of MCS. The vitality subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 vitality subcomponent indicates an improvement.

    Time frame: Baseline and Week 4, 12 and 16

  53. Change From Baseline in the 36-item Short Form (SF-36) Social Subcomponent Score up to Week 16

    SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The social subcomponent is one of the 4 subscales of MCS. The social subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 social subcomponent indicates an improvement.

    Time frame: Baseline and Week 4, 12 and 16

  54. Change From Baseline in the 36-item Short Form (SF-36) Mental Health Subcomponent Score up to Week 16

    SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The mental health subcomponent is one of the 4 subscales of MCS. The mental health subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 mental health subcomponent indicates an improvement.

    Time frame: Baseline and Week 4, 12 and 16

  55. Change From Baseline in the 36-item Short Form (SF-36) Emotional Problems Subcomponent Score up to Week 16

    SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The emotional problem subcomponent is one of the 4 subscales of MCS. The emotional problem subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 emotional problems subcomponent indicates an improvement.

    Time frame: Baseline and Week 4, 12 and 16

  56. Change From Baseline in the Work Productivity and Activity Impairment (WPAI) Subcomponents Score at Week 16

    WPAI contains 4 subcomponents - absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity (overall work impairment/absenteeism plus presenteeism), and activity impairment. Each subcomponent score ranges from 0 to 100, with higher numbers indicating worse outcome. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.

    Time frame: Baseline and week 16

  57. Change From Baseline in the European Quality of Life 5D-5L (EQ-5D-5L) Utility Scores and Its Subcomponents up to 16

    The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. Change from Baseline in 5-level EuroQol 5-dimension (EQ-5D-5L) Utility Scores. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.

    Time frame: Baseline and week 4 and 16

  58. Change From Baseline in Patient-Reported Outcome Measures Information System (PROMIS) Sleep Disturbance up to Week 16

    The Patient-Reported Outcome Measures Information System Sleep Disturbance assess self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This includes perceived difficulties and concerns with getting to sleep or staying asleep, as well as perceptions of the adequacy of and satisfaction with sleep. The items are evaluated on a 5-point Likert scale ranging from 1 = "not at all" to 5 = "very much" with a 7-day recall period. Higher score means more active disease. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.

    Time frame: Baseline and week 4, 12, and 16

07

Results

Posted Oct 24, 2025

Participant flow

Pre-Treatment Period
Participant flow — Pre-Treatment Period
MilestonePlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - PlaceboActive Treatment Period - Deucravacitinib 6 mg QDActive-Treatment Period - Placebo-Deucravacitinib 6 mg QD
Started33633400
Completed33233300
Not completed4100
Withdrew: Other reasons3100
Withdrew: Participant withdrew consent1000
Placebo-Controlled Treatment Period
Participant flow — Placebo-Controlled Treatment Period
MilestonePlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - PlaceboActive Treatment Period - Deucravacitinib 6 mg QDActive-Treatment Period - Placebo-Deucravacitinib 6 mg QD
Started33233300
Completed30930600
Not completed232700
Withdrew: Lack of efficacy1200
Withdrew: Adverse event8600
Withdrew: Participant request to discontinue study treatment2300
Withdrew: Participant withdrew consent41000
Withdrew: Lost to follow-up0100
Withdrew: Administrative reasons by sponsor0100
Withdrew: Other reasons8400
Active Treatment Period
Participant flow — Active Treatment Period
MilestonePlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - PlaceboActive Treatment Period - Deucravacitinib 6 mg QDActive-Treatment Period - Placebo-Deucravacitinib 6 mg QD
Started00309306
Completed00168160
Not completed00141146
Withdrew: Other reasons0013
Withdrew: Lack of efficacy0045
Withdrew: Adverse event0058
Withdrew: Participant request to discontinue study treatment0022
Withdrew: Participant withdrew consent00811
Withdrew: Lost to follow-up0022
Withdrew: Poor/non-compliance0010
Withdrew: Administrative reasons by sponsor0011
Withdrew: Ongoing treatment00117114

Outcome measures

PrimaryPercentage of Participants With ACR 20 Response at Week 16

The ACR 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 20% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication. The 95% CI is calculated using Clopper-Pearson exact method.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With ACR 20 Response at Week 16
percentage of participantsPlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Percentage of Participants With ACR 20 Response at Week 1654.2 (48.7 to 59.6)34.1 (29.1 to 39.5)
Statistical analysis
  • Placebo-Controlled Period - Deucravacitinib 6 mg QD vs Placebo-Controlled Period - Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 2.29 · 95% CI 1.67 to 3.13
SecondaryChange From Baseline in Disease Activity Score 28 C-reactive Protein (DAS28-CRP) at Week 16

DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: \< 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; \>5.1=high disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAS28-CRP indicates an improvement.

Time frame:
Baseline and Week 16
Reported as:
Mean · Score on a Scale
Change From Baseline in Disease Activity Score 28 C-reactive Protein (DAS28-CRP) at Week 16
Score on a ScalePlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Change From Baseline in Disease Activity Score 28 C-reactive Protein (DAS28-CRP) at Week 16-1.4106 ± 1.13277-0.8902 ± 1.10750
Statistical analysis
  • Placebo-Controlled Period - Deucravacitinib 6 mg QD vs Placebo-Controlled Period - Placebo · ANCOVA · p = <0.0001 · Adjusted mean difference: -0.5051 · 95% CI -0.6709 to -0.3392
SecondaryChange From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 16

HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in HAQ-DI indicates an improvement.

Time frame:
Baseline and Week 16
Reported as:
Mean · Score on a Scale
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 16
Score on a ScalePlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 16-0.4103 ± 0.52303-0.2118 ± 0.51583
Statistical analysis
  • Placebo-Controlled Period - Deucravacitinib 6 mg QD vs Placebo-Controlled Period - Placebo · ANCOVA · p = <0.0001 · Adjusted mean difference: -0.1688 · 95% CI -0.2442 to -0.0933
SecondaryPercentage of Participants Meeting Psoriatic Area and Severity Index (PASI) 75 Response at Week 16, in Participants With at Least 3% Body Surface Area (BSA) Involvement and at Least Static Physician's Global Assessment (sPGA) 2 at Baseline

PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value. The 95% CI is calculated using Clopper-Pearson exact method.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Psoriatic Area and Severity Index (PASI) 75 Response at Week 16, in Participants With at Least 3% Body Surface Area (BSA) Involvement and at Least Static Physician's Global Assessment (sPGA) 2 at Baseline
percentage of participantsPlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Percentage of Participants Meeting Psoriatic Area and Severity Index (PASI) 75 Response at Week 16, in Participants With at Least 3% Body Surface Area (BSA) Involvement and at Least Static Physician's Global Assessment (sPGA) 2 at Baseline51.9 (43.9 to 59.8)7.1 (3.7 to 12.0)
Statistical analysis
  • Placebo-Controlled Period - Deucravacitinib 6 mg QD vs Placebo-Controlled Period - Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 14.08 · 95% CI 7.19 to 27.59
SecondaryChange From Baseline in the 36-item Short Form (SF-36) Physical Subcomponent Summary (PCS) Score at Week 16

SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The physical subcomponent summary (PCS) consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The scores range from 0 to 100, with a higher score indicating better quality of life. The PCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 PCS indicates an improvement.

Time frame:
Baseline and Week 16
Reported as:
Mean · Score on a Scale
Change From Baseline in the 36-item Short Form (SF-36) Physical Subcomponent Summary (PCS) Score at Week 16
Score on a ScalePlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Change From Baseline in the 36-item Short Form (SF-36) Physical Subcomponent Summary (PCS) Score at Week 166.410 ± 8.28833.847 ± 7.2929
Statistical analysis
  • Placebo-Controlled Period - Deucravacitinib 6 mg QD vs Placebo-Controlled Period - Placebo · ANCOVA · p = <0.0001 · Adjusted mean difference: 6.631 · 95% CI 3.481 to 9.781
SecondaryPercentage of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Leeds Enthesitis Index (LEI) at Week 16

Percentage of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by Leeds Enthesitis Index (LEI). An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 enthesial sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Leeds Enthesitis Index (LEI) at Week 16
percentage of participantsPlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Percentage of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Leeds Enthesitis Index (LEI) at Week 1648.3 (40.8 to 55.9)46.1 (38.4 to 54.0)
Statistical analysis
  • Placebo-Controlled Period - Deucravacitinib 6 mg QD vs Placebo-Controlled Period - Placebo · Cochran-Mantel-Haenszel · p = 0.5699 · Odds ratio (or): 1.13 · 95% CI 0.74 to 1.75
SecondaryPercentage of Participants Meeting Achievement of Minimal Disease Activity (MDA) at Week 16

Percentage of participants meeting achievement of MDA where an MDA response is achievement of 5 of 7 following outcomes at Week 16: 1. Tender joint count \<= 1 2. Swollen joint count \<=1 3. Psoriasis Area and Severity Index (PASI) \<= 1 or body surface area (BSA) \<= 3% 4. Patient assessment of psoriatic arthiritis (PsA) pain \<= 15 5. Patient Global Assessment of PsA disease activity \<= 20 6. HAQ-DI \<= 0.5 7. Tender enthesial points \<= 1

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Achievement of Minimal Disease Activity (MDA) at Week 16
percentage of participantsPlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Percentage of Participants Meeting Achievement of Minimal Disease Activity (MDA) at Week 1619.0 (15.0 to 23.7)10.2 (7.2 to 13.9)
Statistical analysis
  • Placebo-Controlled Period - Deucravacitinib 6 mg QD vs Placebo-Controlled Period - Placebo · Cochran-Mantel-Haenszel · p = 0.0012 · Odds ratio (or): 2.08 · 95% CI 1.33 to 3.26
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score at Week 16

FACIT-Fatigue evaluates a range of self-reported symptoms over the past week, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience or symptoms of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The recall period is 7 days. Each item is rated on a 5-point Likert scale ranging from 0 = "not at all" to 4 = "very much." Sum scores for the 13 items range from 0 through 52, where higher scores indicate less fatigue. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in FACIT-Fatigue indicates an improvement.

Time frame:
Baseline and Week 16
Reported as:
Mean · Score on a Scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score at Week 16
Score on a ScalePlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score at Week 164.9 ± 8.842.2 ± 8.81
Statistical analysis
  • Placebo-Controlled Period - Deucravacitinib 6 mg QD vs Placebo-Controlled Period - Placebo · ANCOVA · p = <0.0001 · Adjusted mean difference: 2.6 · 95% CI 1.4 to 3.9
SecondaryPercentage of Participants Meeting Dactylitis Resolution at Week 16

Percentage of participants meeting dactylitis resolution at Week 16 among the participants with dactylitis at baseline, where resolution is defined as a tender dactylitis count of 0 in participants with a tender dactylitis count =\> 1 at baseline. The number of digits in hands and feet with dactylitis will be counted by a blinded assessor.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Dactylitis Resolution at Week 16
percentage of participantsPlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Percentage of Participants Meeting Dactylitis Resolution at Week 1659.1 (50.2 to 67.6)43.5 (34.0 to 53.4)
Statistical analysis
  • Placebo-Controlled Period - Deucravacitinib 6 mg QD vs Placebo-Controlled Period - Placebo · Cochran-Mantel-Haenszel · p = 0.0270 · Odds ratio (or): 1.80 · 95% CI 1.07 to 3.03
SecondaryChange From Baseline in PsA-modified Sharp-van Der Heijde (SvdH) Score at Week 16

The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage. Change from baseline reflects progression or improvement; a decrease suggests reduced damage or improvement.

Time frame:
Baseline and Week 16
Reported as:
Mean · Score on a Scale
Change From Baseline in PsA-modified Sharp-van Der Heijde (SvdH) Score at Week 16
Score on a ScalePlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Change From Baseline in PsA-modified Sharp-van Der Heijde (SvdH) Score at Week 160.3980 ± 2.008520.5757 ± 2.73874
Statistical analysis
  • Placebo-Controlled Period - Deucravacitinib 6 mg QD vs Placebo-Controlled Period - Placebo · ANCOVA · p = 0.7194 · Adjusted mean difference: 0.1596 · 95% CI -0.7114 to 1.0306
SecondaryPercentage of Participants With ACR 20 Response up to Week 16

The ACR 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 20% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication. The 95% CI is calculated using Clopper-Pearson exact method.

Time frame:
Week 2, 4, 8, 12, and 16
Reported as:
Number · percentage of participants
Percentage of Participants With ACR 20 Response up to Week 16
percentage of participantsPlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 214.0 (10.5 to 18.2)13.8 (10.3 to 17.9)
Week 431.5 (26.6 to 36.8)19.5 (15.4 to 24.1)
Week 842.6 (37.2 to 48.0)30.5 (25.6 to 35.8)
Week 1249.1 (43.6 to 54.6)31.1 (26.2 to 36.4)
Week 1654.2 (48.7 to 59.6)34.1 (29.1 to 39.5)
SecondaryPercentage of Participants With ACR 50 Response up to Week 16

The ACR 50 definition of improvement is a 50% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 50% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication. The 95% CI is calculated using Clopper-Pearson exact method.

Time frame:
Week 2, 4, 8, 12, and 16
Reported as:
Number · percentage of participants
Percentage of Participants With ACR 50 Response up to Week 16
percentage of participantsPlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 22.1 (0.8 to 4.2)1.2 (0.3 to 3.0)
Week 47.7 (5.1 to 11.1)3.6 (1.9 to 6.2)
Week 817.0 (13.1 to 21.4)9.6 (6.6 to 13.3)
Week 1222.6 (18.3 to 27.5)10.8 (7.7 to 14.6)
Week 1624.7 (20.2 to 29.7)13.5 (10.0 to 17.6)
SecondaryPercentage of Participants With ACR 70 Response up to Week 16

The ACR 70 definition of improvement is a 70% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 70% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication. The 95% CI is calculated using Clopper-Pearson exact method.

Time frame:
Week 2, 4, 8, 12, and 16
Reported as:
Number · percentage of participants
Percentage of Participants With ACR 70 Response up to Week 16
percentage of participantsPlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 20.3 (0.0 to 1.6)0.0 (0.0 to 1.1)
Week 41.8 (0.7 to 3.8)0.0 (0.0 to 1.1)
Week 85.7 (3.4 to 8.7)3.0 (1.4 to 5.4)
Week 127.4 (4.9 to 10.8)3.6 (1.9 to 6.2)
Week 1611.6 (8.4 to 15.5)5.4 (3.2 to 8.4)
SecondaryChange From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) up to Week 16

HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in HAQ-DI indicates an improvement.

Time frame:
Baseline and Week 2, 4, 8, 12, and 16
Reported as:
Mean · Score on a Scale
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) up to Week 16
Score on a ScalePlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 2 (n=324, 323)-0.1655 ± 0.37744-0.1250 ± 0.38243
Week 4 (n=325, 326)-0.2412 ± 0.43862-0.1614 ± 0.39402
Week 8 (n=327, 326)-0.3119 ± 0.50219-0.1963 ± 0.47057
Week 12 (n= 326, 327)-0.3589 ± 0.49384-0.1957 ± 0.53080
Week 16 (n=326, 327)-0.4103 ± 0.52303-0.2118 ± 0.51583
SecondaryPercentage of Participants Who Achieve a Clinically Meaningful Improvement in Health Assessment Questionnaire - Disability Index (HAQ-DI) up to Week 16 Among Participants With a HAQ-DI Score ≥0.35 at Baseline

HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For each item in the questionnaire, the level of activity is scored from 0 to 3, with 0 representing "no difficulty," 1 representing "some difficulty," 2 representing "much difficulty," and 3 representing "unable to do." increasing scores for the 8 disability categories indicate increasing level of difficulty. HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered. Clinically meaningful improvement was defined as ≥0.35improvement from baseline.

Time frame:
Baseline and Week 2, 4, 8, 12, and 16
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieve a Clinically Meaningful Improvement in Health Assessment Questionnaire - Disability Index (HAQ-DI) up to Week 16 Among Participants With a HAQ-DI Score ≥0.35 at Baseline
Percentage of ParticipantsPlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 228.0 (23.1 to 33.3)28.0 (23.1 to 33.4)
Week 441.4 (35.9 to 47.1)30.9 (25.8 to 36.4)
Week 845.5 (39.9 to 51.2)34.2 (28.9 to 39.8)
Week 1249.7 (44.0 to 55.4)39.7 (34.2 to 45.5)
Week 1651.3 (45.6 to 56.9)38.8 (33.3 to 44.5)
SecondaryPercentage of Participants Meeting Psoriatic Area and Severity Index (PASI) 75 Response up to Week 16, in Participants With at Least 3% Body Surface Area (BSA) Involvement and at Least Static Physician's Global Assessment (sPGA) 2 at Baseline

PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value. The 95% CI is calculated using Clopper-Pearson exact method.

Time frame:
Week 4, 8, 12 and 16
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Psoriatic Area and Severity Index (PASI) 75 Response up to Week 16, in Participants With at Least 3% Body Surface Area (BSA) Involvement and at Least Static Physician's Global Assessment (sPGA) 2 at Baseline
percentage of participantsPlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 411.7 (7.2 to 17.7)6.5 (3.3 to 11.3)
Week 831.5 (24.4 to 39.2)10.0 (5.9 to 15.5)
Week 1242.6 (34.9 to 50.6)8.8 (5.0 to 14.1)
Week 1651.9 (43.9 to 59.8)7.1 (3.7 to 12.0)
SecondaryPercentage of Participants Meeting Psoriatic Area and Severity Index (PASI) 90 Response up to Week 16, in Participants With at Least 3% Body Surface Area (BSA) Involvement and at Least Static Physician's Global Assessment (sPGA) 2 at Baseline

PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 90 is the number of participants who experience at least a 90% improvement in PASI score as compared with the baseline value. The 95% CI is calculated using Clopper-Pearson exact method.

Time frame:
Week 4, 8, 12 and 16
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Psoriatic Area and Severity Index (PASI) 90 Response up to Week 16, in Participants With at Least 3% Body Surface Area (BSA) Involvement and at Least Static Physician's Global Assessment (sPGA) 2 at Baseline
percentage of participantsPlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 44.3 (1.8 to 8.7)1.8 (0.4 to 5.1)
Week 814.8 (9.7 to 21.2)1.8 (0.4 to 5.1)
Week 1220.4 (14.5 to 27.4)3.5 (1.3 to 7.5)
Week 1625.3 (18.8 to 32.7)1.8 (0.4 to 5.1)
SecondaryPercentage of Participants Meeting Psoriatic Area and Severity Index (PASI) 100 Response up to Week 16, in Participants With at Least 3% Body Surface Area (BSA) Involvement and at Least Static Physician's Global Assessment (sPGA) 2 at Baseline

PASI is a measure of the average erythema, induration thickness, and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 100 is the number of participants who experience at least a 100% improvement in PASI score as compared with the baseline value. The 95% CI is calculated using Clopper-Pearson exact method.

Time frame:
Week 4, 8, 12 and 16
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Psoriatic Area and Severity Index (PASI) 100 Response up to Week 16, in Participants With at Least 3% Body Surface Area (BSA) Involvement and at Least Static Physician's Global Assessment (sPGA) 2 at Baseline
percentage of participantsPlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 41.9 (0.4 to 5.3)1.2 (0.1 to 4.2)
Week 88.0 (4.3 to 13.3)0.6 (0.0 to 3.2)
Week 1211.1 (6.7 to 17.0)1.8 (0.4 to 5.1)
Week 1614.2 (9.2 to 20.5)1.8 (0.4 to 5.1)
SecondaryChange From Baseline in the 36-item Short Form (SF-36) Physical Subcomponent Summary (PCS) Score up to Week 16

SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The physical subcomponent summary (PCS) consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The scores range from 0 to 100, with a higher score indicating poor quality of life. The PCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 PCS indicates an improvement.

Time frame:
Baseline and Week 4, 12 and 16
Reported as:
Mean · Score on a Scale
Change From Baseline in the 36-item Short Form (SF-36) Physical Subcomponent Summary (PCS) Score up to Week 16
Score on a ScalePlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 43.760 ± 6.27683.326 ± 5.7315
Week 126.021 ± 7.58093.916 ± 7.6614
Week 166.410 ± 8.28833.847 ± 7.2929
SecondaryPercentage of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Leeds Enthesitis Index (LEI) up to Week 16

Percentage of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by Leeds Enthesitis Index (LEI). An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 enthesial sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden.

Time frame:
Week 4, 8, 12 and 16
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Leeds Enthesitis Index (LEI) up to Week 16
percentage of participantsPlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 431.5 (24.7 to 38.8)32.9 (25.9 to 40.6)
Week 844.4 (37.0 to 52.0)47.9 (40.1 to 55.8)
Week 1247.2 (39.7 to 54.8)50.3 (42.5 to 58.1)
Week 1648.3 (40.8 to 55.9)46.1 (38.4 to 54.0)
SecondaryPercentage of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Spondyloarthritis Research Consortium of Canada (SPARCC) up to Week 16

Percentage of participants meeting enthesitis resolution (score of 0) among participants with enthesitis at Baseline by SPARCC. The SPARCC Enthesitis Index has a 0 to 16 score that is derived from the evaluation of 8 locations: the greater trochanter (right \\\[R\\\]/left \\\[L\\\]), quadriceps tendon insertion into the patella (R/L), patellar ligament insertion into the patella and tibial tuberosity (R/L), Achilles tendon insertion (R/L), plantar fascia insertion (R/L), medial and lateral epicondyles (R/L), and supraspinatus insertion (R/L). A higher count indicates a higher enthesitis burden based on the current evaluation.

Time frame:
Week 4, 8, 12 and 16
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Enthesitis Resolution (Score of 0) Among Participants With Enthesitis at Baseline by Spondyloarthritis Research Consortium of Canada (SPARCC) up to Week 16
percentage of participantsPlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 419.4 (14.4 to 25.4)25.6 (19.8 to 32.0)
Week 834.7 (28.4 to 41.5)30.8 (24.6 to 37.5)
Week 1236.6 (30.1 to 43.4)34.6 (28.2 to 41.4)
Week 1645.8 (39.1 to 52.7)34.1 (27.8 to 40.9)
SecondaryPercentage of Participants Meeting Achievement of Minimal Disease Activity (MDA) up to Week 16

Percentage of participants meeting achievement of MDA where an MDA response is achievement of 5 of 7 following outcomes at Week 16: 1. Tender joint count \<= 1 2. Swollen joint count \<=1 3. Psoriasis Area and Severity Index (PASI) \<= 1 or body surface area (BSA) \<= 3% 4. Patient assessment of psoriatic arthiritis (PsA) pain \<= 15 5. Patient Global Assessment of PsA disease activity \<= 20 6. HAQ-DI \<= 0.5 7. Tender enthesial points \<= 1

Time frame:
Week 4, 8, 12, and 16
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Achievement of Minimal Disease Activity (MDA) up to Week 16
percentage of participantsPlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 46.0 (3.7 to 9.0)3.0 (1.4 to 5.4)
Week 810.1 (7.1 to 13.9)6.6 (4.2 to 9.8)
Week 1214.0 (10.5 to 18.2)7.2 (4.7 to 10.5)
Week 1619.0 (15.0 to 23.7)10.2 (7.2 to 13.9)
SecondaryChange From Baseline in the 36-item Short Form (SF-36) Mental Component Summary (MCS) Score up to Week 16

SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The mental component summary (MCS) of the SF-36 consists of these 4 subscales: Vitality, Social functioning, Role-emotional, Mental health. The scores range from 0 to 100, with a higher score indicating poor quality of life. The MCS summary scores will be calculated by taking a weighted linear combination of the individual subscales. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 MCS indicates an improvement.

Time frame:
Baseline and Week 4, 12 and 16
Reported as:
Mean · Score on a Scale
Change From Baseline in the 36-item Short Form (SF-36) Mental Component Summary (MCS) Score up to Week 16
Score on a ScalePlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 40.814 ± 7.50820.634 ± 7.3796
Week 122.056 ± 8.42060.034 ± 8.3926
Week 162.588 ± 8.34420.358 ± 8.1559
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score up to Week 16

FACIT-Fatigue evaluates a range of self-reported symptoms over the past week, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience or symptoms of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The recall period is 7 days. Each item is rated on a 5-point Likert scale ranging from 0 = "not at all" to 4 = "very much." Sum scores for the 13 items range from 0 through 52, where higher scores indicate less fatigue. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in FACIT-Fatigue indicates an improvement.

Time frame:
Baseline and Week 2, 4, 8, 12 and 16
Reported as:
Mean · Score on a Scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score up to Week 16
Score on a ScalePlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 22.2 ± 7.312.3 ± 6.52
Week 42.5 ± 7.482.3 ± 7.67
Week 84.5 ± 8.682.8 ± 9.64
Week 124.3 ± 8.981.8 ± 8.97
Week 164.9 ± 8.842.2 ± 8.81
SecondaryPercentage of Participants Meeting Dactylitis Resolution up to Week 16

Percentage of participants meeting dactylitis resolution at Week 16 among the participants with dactylitis at baseline, where resolution is defined as a tender dactylitis count of 0 in participants with a tender dactylitis count =\> 1 at baseline. The number of digits in hands and feet with dactylitis will be counted by a blinded assessor.

Time frame:
Week 4, 8, 12 and 16
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Dactylitis Resolution up to Week 16
percentage of participantsPlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 436.4 (28.2 to 45.2)33.3 (24.6 to 43.1)
Week 844.7 (36.0 to 53.6)43.5 (34.0 to 53.4)
Week 1254.5 (45.7 to 63.2)48.1 (38.4 to 58.0)
Week 1659.1 (50.2 to 67.6)43.5 (34.0 to 53.4)
SecondaryChange From Baseline in Psoriatic Arthritis Impact of Disease (PsAID) 12 Score up to Week 16

The Psoriatic Arthritis Impact of Disease (PsAID) is a 12-item self-report that measures PsA symptoms and impact of disease. Each item is scored on a 0 to 10 numeric rating scale with a 1-week recall period. The PsAID has a total score, with a higher value indicating worse health. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in PsAID indicates an improvement.

Time frame:
Baseline and Week 2, 4, 8, 12 and 16
Reported as:
Mean · Score on a Scale
Change From Baseline in Psoriatic Arthritis Impact of Disease (PsAID) 12 Score up to Week 16
Score on a ScalePlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 2-0.807 ± 1.3327-0.652 ± 1.2524
Week 4-1.164 ± 1.5433-0.836 ± 1.5580
Week 8-1.545 ± 1.9037-0.991 ± 1.9281
Week 12-1.761 ± 2.0074-0.883 ± 1.9677
Week 16-1.851 ± 2.0440-1.015 ± 1.9955
SecondaryChange From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) Score up to Week 16

The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \\\[cm\\\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. The DAPSA score ranges from 0 to 154, with a higher score indicating more disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAPSA indicates an improvement.

Time frame:
Baseline and Week 2, 4, 8, 12 and 16
Reported as:
Mean · Score on a Scale
Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) Score up to Week 16
Score on a ScalePlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 2-7.6211 ± 13.23221-7.0045 ± 11.71166
Week 4-12.5643 ± 14.38734-10.1201 ± 13.64766
Week 8-16.6770 ± 16.71038-12.3610 ± 15.70632
Week 12-19.8346 ± 17.22613-13.2671 ± 17.41524
Week 16-20.7263 ± 18.08249-13.4075 ± 17.31116
SecondaryPercentage of Participants With Achievement of Disease Activity Index for Psoriatic Arthritis (DAPSA) Low Disease Activity Response up to Week 16

The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \\\[cm\\\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. A higher DAPSA score indicated more active disease activity.

Time frame:
Baseline and Week 2, 4, 8, 12 and 16
Reported as:
Number · percentage of participants
Percentage of Participants With Achievement of Disease Activity Index for Psoriatic Arthritis (DAPSA) Low Disease Activity Response up to Week 16
percentage of participantsPlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 26.5 (4.1 to 9.7)4.5 (2.5 to 7.3)
Week 413.7 (10.2 to 17.8)9.9 (6.9 to 13.6)
Week 821.4 (17.2 to 26.2)16.5 (12.7 to 20.9)
Week 1228.9 (24.1 to 34.0)17.4 (13.5 to 21.9)
Week 1626.2 (21.6 to 31.2)18.9 (14.8 to 23.5)
SecondaryPercentage of Participants With Achievement of Disease Activity Index for Psoriatic Arthritis (DAPSA) Disease Remission up to Week 16

The Disease Activity Index for Psoriatic Arthritis Score is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender joint count (0-68), swollen joint count (0-66), Participant Global Assessment of Disease Activity (0 to 10 cm VAS, 0= excellent and 10= poor), Participant Global Assessment of Pain (0 to 10 centimeter \\\[cm\\\] visual analog scale (VAS), 0= no pain, 10= worst possible pain), and C-reactive protein. A higher DAPSA score indicated more active disease activity. A score 0 signifies remission.

Time frame:
Baseline and Week 2, 4, 8, 12 and 16
Reported as:
Number · percentage of participants
Percentage of Participants With Achievement of Disease Activity Index for Psoriatic Arthritis (DAPSA) Disease Remission up to Week 16
percentage of participantsPlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 20.3 (0.0 to 1.6)0.0 (0.0 to 1.1)
Week 41.5 (0.5 to 3.4)0.6 (0.1 to 2.1)
Week 83.0 (1.4 to 5.4)1.8 (0.7 to 3.9)
Week 125.7 (3.4 to 8.7)1.8 (0.7 to 3.9)
Week 168.6 (5.9 to 12.2)2.7 (1.2 to 5.1)
SecondaryPercentage of Participants Meeting Achievement of Physician Global Assessment-Fingernails (PGA-F) of 0/1 up to Week 16

The PGA-F is a 5-point scale used to assess fingernails separately for nail bed signs and nail matrix signs of disease. A global score of between 0 indicating clear, and 4 indicating severe. The overall condition of the fingernails is rated on a 5-point scale: 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, and 4 = severe.

Time frame:
Week 2, 4, 8, 12 and 16
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Achievement of Physician Global Assessment-Fingernails (PGA-F) of 0/1 up to Week 16
percentage of participantsPlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 412.7 (6.0 to 22.7)6.6 (1.8 to 15.9)
Week 819.7 (11.2 to 30.9)16.4 (8.2 to 28.1)
Week 1216.9 (9.0 to 27.7)21.3 (11.9 to 33.7)
Week 1623.9 (14.6 to 35.5)14.8 (7.0 to 26.2)
SecondaryChange From Baseline in Disease Activity Score 28 C-reactive Protein (DAS28-CRP) up to Week 16

DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: \\\< 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; \\\>5.1=high disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in DAS28-CRP indicates an improvement.

Time frame:
Baseline and Week 2, 4, 8, 12 and 16
Reported as:
Mean · Score on a Scale
Change From Baseline in Disease Activity Score 28 C-reactive Protein (DAS28-CRP) up to Week 16
Score on a ScalePlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 2-0.4028 ± 0.77126-0.4006 ± 0.70508
Week 4-0.7655 ± 0.90092-0.6468 ± 0.82146
Week 8-1.0820 ± 1.02041-0.7727 ± 0.99752
Week 12-1.3360 ± 1.13745-0.8450 ± 1.09776
Week 16-1.4106 ± 1.13277-0.8902 ± 1.10750
SecondaryPercentage of Participants Meeting Disease Activity Score 28 C-reactive Protein (DAS28-CRP) Low Disease Activity Response up to Week 16

DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: \\\< 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; \\\>5.1=high disease activity.

Time frame:
Week 2, 4, 8, 12 and 16
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Disease Activity Score 28 C-reactive Protein (DAS28-CRP) Low Disease Activity Response up to Week 16
percentage of participantsPlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 25.4 (3.2 to 8.3)4.8 (2.8 to 7.7)
Week 49.8 (6.9 to 13.5)6.0 (3.7 to 9.1)
Week 811.3 (8.1 to 15.2)9.3 (6.4 to 12.9)
Week 1214.3 (10.7 to 18.5)11.7 (8.4 to 15.6)
Week 1615.2 (11.5 to 19.5)8.1 (5.4 to 11.5)
SecondaryPercentage of Participants Meeting Disease Activity Score 28 C-reactive Protein (DAS28-CRP) Disease Remission up to Week 16

DAS28-CRP is a composite of how many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints but excluding DIPs), wrists, elbows, shoulders, and knees are swollen and/or tender out of a total of 28; CRP in the blood to measure the degree of inflammation, and participant global assessment of disease activity. The results are combined to produce the DAS28-CRP score that range from 1.0 to 9.4, which correlates with the extent of disease activity: \\\< 2.6=disease remission; 2.6 - 3.2=low disease activity; 3.2-5.1=moderate disease activity; \\\>5.1=high disease activity.

Time frame:
Week 2, 4, 8, 12 and 16
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Disease Activity Score 28 C-reactive Protein (DAS28-CRP) Disease Remission up to Week 16
percentage of participantsPlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 22.1 (0.8 to 4.2)2.1 (0.8 to 4.3)
Week 48.0 (5.4 to 11.5)5.4 (3.2 to 8.4)
Week 814.9 (11.3 to 19.1)8.7 (5.9 to 12.2)
Week 1220.8 (16.6 to 25.6)9.0 (6.1 to 12.6)
Week 1622.3 (18.0 to 27.2)13.8 (10.3 to 17.9)
SecondaryChange From Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS) up to Week 16

The Psoriatic Arthritis Disease Activity Score (PASDAS) is a composite measure calculated from the Physician Global Assessment of PsA, the Participant Global Assessment of Disease Activity, the Short Form-36 PCS, the swollen joint count, the tender joint count, the Enthesitis (LEI), the Dactylitis (LDI) (Basic), and the High-sensitivity C-reactive protein (hsCRP). The range of PASDAS is 0-10. Higher score means more active disease. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.

Time frame:
Baseline and Week 4, 12 and 16
Reported as:
Mean · Score on a Scale
Change From Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS) up to Week 16
Score on a ScalePlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 4-1.0405 ± 1.03004-0.8258 ± 0.97038
Week 12-1.7675 ± 1.37563-1.0780 ± 1.33036
Week 16-1.9064 ± 1.45258-1.1026 ± 1.31166
SecondaryChange From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) up to Week 16

Four domains are used to calculate the modified Composite Psoriatic Disease Activity Index (mCPDAI): joints (66 swollen joint count and 68 tender joint count; Health Assessment Questionnaire), skin (PASI and DLQI), dactylitis (a simple count of each digit involved), and enthesitis (number of tendons/fascia insertion sites showing enthesitis scored from 0 to 4, based on palpation of Achilles tendon and bilateral plantar fasciae insertion). The mCPDAI is scored using a 4 point scale from 0 (no disease activity) to 3 (most severe disease activity), giving an mCPDAI score range of 0 through 12. A higher score indicates more active disease activity. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.

Time frame:
Baseline and Week 4, 8, 12 and 16
Reported as:
Mean · Score on a Scale
Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) up to Week 16
Score on a ScalePlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 4-1.2 ± 1.81-0.8 ± 1.61
Week 8-1.7 ± 2.09-1.2 ± 1.89
Week 12-2.1 ± 2.16-1.3 ± 2.01
Week 16-2.2 ± 2.22-1.3 ± 1.96
SecondaryPercentage of Participants With Achievement of Psoriatic Arthritis Response Criteria (PsARC) up to Week 16

The Psoriatic Arthritis Response Criteria (PsARC) consists of 4 measurements: tender joint count, swollen joint count, Physician Global Assessment of PsA, and Participant Global Assessment of Disease Activity. In order to be classified as a PsARC responder, participants must achieve improvement in 2 of 4 measures, 1 of which must be joint pain or swelling, without worsening in any measure. Improvement in each of the measures is defined below: 1) Decrease of ≥ 30% in tender joint counts; 2) Decrease of ≥ 30% in swollen joint counts; 3) Decrease of ≥ 20% in Physician Global Assessment of PsA; 4) Decrease of ≥ 20% in Participant's Global Assessment of Disease Activity

Time frame:
Week 2, 4, 8, 12 and 16
Reported as:
Number · percentage of participants
Percentage of Participants With Achievement of Psoriatic Arthritis Response Criteria (PsARC) up to Week 16
percentage of participantsPlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 225.9 (21.3 to 30.9)21.9 (17.5 to 26.7)
Week 447.0 (41.6 to 52.5)31.1 (26.2 to 36.4)
Week 851.5 (46.0 to 56.9)41.3 (36.0 to 46.8)
Week 1255.4 (49.9 to 60.8)39.8 (34.5 to 45.3)
Week 1662.5 (57.1 to 67.7)40.1 (34.8 to 45.6)
SecondaryPercentage of Participants Meeting Achievement of Improvement of Bath Ankylosing Spondylitis Disease Activity (BASDAI) Score up to Week 16

BASDAI consists of a 0 to 10 scale measuring discomfort, pain, and fatigue in response to 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: 1) Fatigue (medical); 2) Spinal pain; 3) Joint pain and swelling; 4) Areas of localized tenderness; 5) Morning stiffness duration; 6) Morning stiffness severity. A higher count indicates worse disease. Each individual question response is scaled to a 0-10 score by dividing by 10, and the BASDAI is derived using the following formula: BASDAI = ((Q1 + Q2 + Q3 + Q4) + ((Q5 + Q6) / 2)) / 5

Time frame:
Week 2, 4, 8, 12 and 16
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Achievement of Improvement of Bath Ankylosing Spondylitis Disease Activity (BASDAI) Score up to Week 16
percentage of participantsPlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 27.3 (2.0 to 17.6)6.1 (1.3 to 16.9)
Week 410.9 (4.1 to 22.2)16.3 (7.3 to 29.7)
Week 818.2 (9.1 to 30.9)14.3 (5.9 to 27.2)
Week 1225.5 (14.7 to 39.0)16.3 (7.3 to 29.7)
Week 1625.5 (14.7 to 39.0)14.3 (5.9 to 27.2)
SecondaryPercentage of Participants Meeting Achievement of Total PsA-modified SvdH Scores Response of <= 0 at Week 16

The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Scores Response of <= 0 at Week 16
percentage of participantsPlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Scores Response of <= 0 at Week 1659.5 (54.1 to 64.8)53.9 (48.4 to 59.3)
SecondaryPercentage of Participants Meeting Achievement of Total PsA-modified SvdH Scores Response of <= 0.5 at Week 16

The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Scores Response of <= 0.5 at Week 16
percentage of participantsPlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Scores Response of <= 0.5 at Week 1662.8 (57.4 to 68.0)60.5 (55.0 to 65.8)
SecondaryPercentage of Participants Meeting Achievement of Total PsA-modified SvdH Scores Response of <= Smallest Detectable Change (SDC) at Week 16

The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage. SDC is calculated as 1.96\* standard deviation of the paired differences of change from baseline/ square root of (2\*k); k is the number of reviewers and is default to 2 in this study.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Scores Response of <= Smallest Detectable Change (SDC) at Week 16
percentage of participantsPlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Scores Response of <= Smallest Detectable Change (SDC) at Week 1667.6 (62.3 to 72.5)66.2 (60.8 to 71.2)
SecondaryPercentage of Participants Meeting Achievement of Total PsA-modified SvdH Erosion Scores Response of <= 0 at Week 16

The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Erosion Scores Response of <= 0 at Week 16
percentage of participantsPlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Erosion Scores Response of <= 0 at Week 1660.4 (55.0 to 65.7)56.6 (51.1 to 62.0)
SecondaryPercentage of Participants Meeting Achievement of Total PsA-modified SvdH Erosion Scores Response of <= 0.5 at Week 16

The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Erosion Scores Response of <= 0.5 at Week 16
percentage of participantsPlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Erosion Scores Response of <= 0.5 at Week 1664.3 (58.9 to 69.4)62.9 (57.4 to 68.1)
SecondaryPercentage of Participants Meeting Achievement of Total PsA-modified SvdH Erosion Scores Response of <= SDC at Week 16

The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage. SDC is calculated as 1.96\* standard deviation of the paired differences of change from baseline/ square root of (2\*k); k is the number of reviewers and is default to 2 in this study.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Erosion Scores Response of <= SDC at Week 16
percentage of participantsPlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Erosion Scores Response of <= SDC at Week 1666.7 (61.3 to 71.7)66.8 (61.4 to 71.8)
SecondaryPercentage of Participants Meeting Achievement of Total PsA-modified SvdH Joint Space Narrowing (JSN) Scores Response of <= 0 at Week 16

The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Joint Space Narrowing (JSN) Scores Response of <= 0 at Week 16
percentage of participantsPlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Joint Space Narrowing (JSN) Scores Response of <= 0 at Week 1667.6 (62.3 to 72.5)64.4 (59.0 to 69.5)
SecondaryPercentage of Participants Meeting Achievement of Total PsA-modified SvdH Joint Space Narrowing (JSN) Scores Response of <= 0.5 at Week 16

The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Joint Space Narrowing (JSN) Scores Response of <= 0.5 at Week 16
percentage of participantsPlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Joint Space Narrowing (JSN) Scores Response of <= 0.5 at Week 1670.5 (65.3 to 75.4)68.9 (63.6 to 73.8)
SecondaryPercentage of Participants Meeting Achievement of Total PsA-modified SvdH Joint Space Narrowing (JSN) Scores Response of <= SDC at Week 16

The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage. SDC is calculated as 1.96\* standard deviation of the paired differences of change from baseline/ square root of (2\*k); k is the number of reviewers and is default to 2 in this study.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Joint Space Narrowing (JSN) Scores Response of <= SDC at Week 16
percentage of participantsPlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Percentage of Participants Meeting Achievement of Total PsA-modified SvdH Joint Space Narrowing (JSN) Scores Response of <= SDC at Week 1670.5 (65.3 to 75.4)68.9 (63.6 to 73.8)
SecondaryChange From Baseline in PsA-modified SvdH Erosion Scores Response at Week 16

The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.

Time frame:
Baseline and Week 16
Reported as:
Mean · Score on a Scale
Change From Baseline in PsA-modified SvdH Erosion Scores Response at Week 16
Score on a ScalePlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Change From Baseline in PsA-modified SvdH Erosion Scores Response at Week 160.32 ± 1.4170.37 ± 1.326
SecondaryChange From Baseline in PsA-modified SvdH JSN Scores Response at Week 16

The PsA-modified Sharp-van der Heijde (SvdH) score is a radiographic tool used to assess structural joint damage in psoriatic arthritis. It evaluates erosions, joint space narrowing, (sub)luxation, and ankylosis in 52 joints of the hands and feet, including distal interphalangeal joints. Erosions are scored 0-3 and joint space narrowing 0-4. The total score ranges from 0 to 528 (erosions: max 320; joint space narrowing: max 208). Higher scores indicate greater joint damage.

Time frame:
Baseline and Week 16
Reported as:
Mean · Score on a Scale
Change From Baseline in PsA-modified SvdH JSN Scores Response at Week 16
Score on a ScalePlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Change From Baseline in PsA-modified SvdH JSN Scores Response at Week 160.09 ± 0.7030.14 ± 0.485
SecondaryChange From Baseline in the 36-item Short Form (SF-36) Physical Subcomponent Summary Score up to Week 16

SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The physical sub component is one of the 4 subscales of PCS. The physical subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 physical sub-component indicates an improvement.

Time frame:
Baseline and Week 4, 12 and 16
Reported as:
Mean · Score on a Scale
Change From Baseline in the 36-item Short Form (SF-36) Physical Subcomponent Summary Score up to Week 16
Score on a ScalePlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 47.923 ± 17.94836.908 ± 17.0306
Week 1213.615 ± 20.57257.784 ± 22.4709
Week 1615.414 ± 22.39308.226 ± 22.1449
SecondaryChange From Baseline in the 36-item Short Form (SF-36) Role Activity Subcomponent Summary Score up to Week 16

SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The role activity sub component is one of the 4 subscales of PCS. The role activity subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 role activity indicates an improvement.

Time frame:
Baseline and Week 4, 12 and 16
Reported as:
Mean · Score on a Scale
Change From Baseline in the 36-item Short Form (SF-36) Role Activity Subcomponent Summary Score up to Week 16
Score on a ScalePlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 46.962 ± 20.69637.058 ± 18.7454
Week 1213.096 ± 22.73728.365 ± 21.1286
Week 1613.152 ± 23.63707.913 ± 20.8035
SecondaryChange From Baseline in the 36-item Short Form (SF-36) Bodily Pain Subcomponent Summary Score up to Week 16

SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The bodily pain sub component is one of the 4 subscales of PCS. The bodily pain subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 bodily pain subcomponent indicates an improvement.

Time frame:
Baseline and Week 4, 12 and 16
Reported as:
Mean · Score on a Scale
Change From Baseline in the 36-item Short Form (SF-36) Bodily Pain Subcomponent Summary Score up to Week 16
Score on a ScalePlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 410.0 ± 16.528.5 ± 15.47
Week 1216.6 ± 20.969.4 ± 19.66
Week 1618.2 ± 21.8310.0 ± 18.85
SecondaryChange From Baseline in the 36-item Short Form (SF-36) General Health Perceptions Subcomponent Summary Score up to Week 16

SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The general health perceptions sub component is one of the 4 subscales of PCS. The general health perceptions subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 general health perceptions subcomponent indicates an improvement.

Time frame:
Baseline and Week 4, 12 and 16
Reported as:
Mean · Score on a Scale
Change From Baseline in the 36-item Short Form (SF-36) General Health Perceptions Subcomponent Summary Score up to Week 16
Score on a ScalePlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 46.1 ± 12.955.1 ± 13.35
Week 128.4 ± 15.134.8 ± 15.02
Week 168.9 ± 16.004.6 ± 14.85
SecondaryChange From Baseline in the 36-item Short Form (SF-36) Vitality Subcomponent Score up to Week 16

SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The vitality subcomponent is one of the 4 subscales of MCS. The vitality subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 vitality subcomponent indicates an improvement.

Time frame:
Baseline and Week 4, 12 and 16
Reported as:
Mean · Score on a Scale
Change From Baseline in the 36-item Short Form (SF-36) Vitality Subcomponent Score up to Week 16
Score on a ScalePlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 44.558 ± 14.68294.327 ± 14.3971
Week 128.442 ± 17.92834.308 ± 17.6763
Week 169.682 ± 16.44744.893 ± 17.5265
SecondaryChange From Baseline in the 36-item Short Form (SF-36) Social Subcomponent Score up to Week 16

SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The social subcomponent is one of the 4 subscales of MCS. The social subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 social subcomponent indicates an improvement.

Time frame:
Baseline and Week 4, 12 and 16
Reported as:
Mean · Score on a Scale
Change From Baseline in the 36-item Short Form (SF-36) Social Subcomponent Score up to Week 16
Score on a ScalePlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 46.69 ± 20.6104.62 ± 20.737
Week 1211.96 ± 23.9904.88 ± 22.539
Week 1613.80 ± 22.9604.74 ± 23.303
SecondaryChange From Baseline in the 36-item Short Form (SF-36) Mental Health Subcomponent Score up to Week 16

SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The mental health subcomponent is one of the 4 subscales of MCS. The mental health subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 mental health subcomponent indicates an improvement.

Time frame:
Baseline and Week 4, 12 and 16
Reported as:
Mean · Score on a Scale
Change From Baseline in the 36-item Short Form (SF-36) Mental Health Subcomponent Score up to Week 16
Score on a ScalePlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 42.1 ± 14.172.2 ± 13.99
Week 124.9 ± 16.411.4 ± 16.38
Week 165.5 ± 15.981.5 ± 15.78
SecondaryChange From Baseline in the 36-item Short Form (SF-36) Emotional Problems Subcomponent Score up to Week 16

SF-36 is a generic 36-item questionnaire measuring health-related quality of life. The emotional problem subcomponent is one of the 4 subscales of MCS. The emotional problem subcomponent scores will be calculated by taking a weighted linear combination of the individual question. The score ranges from 0 to 100, with higher values indication poor quality of life. Change from baseline is defined as value at post-baseline visit. A negative change from baseline in SF-36 emotional problems subcomponent indicates an improvement.

Time frame:
Baseline and Week 4, 12 and 16
Reported as:
Mean · Score on a Scale
Change From Baseline in the 36-item Short Form (SF-36) Emotional Problems Subcomponent Score up to Week 16
Score on a ScalePlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 42.718 ± 20.11332.128 ± 20.1154
Week 125.846 ± 21.40700.718 ± 21.0925
Week 167.438 ± 22.65172.370 ± 21.4931
SecondaryChange From Baseline in the Work Productivity and Activity Impairment (WPAI) Subcomponents Score at Week 16

WPAI contains 4 subcomponents - absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity (overall work impairment/absenteeism plus presenteeism), and activity impairment. Each subcomponent score ranges from 0 to 100, with higher numbers indicating worse outcome. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.

Time frame:
Baseline and week 16
Reported as:
Mean · Score on a Scale
Change From Baseline in the Work Productivity and Activity Impairment (WPAI) Subcomponents Score at Week 16
Score on a ScalePlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
WPAI Absenteeism-3.30 ± 20.7771.23 ± 19.389
WPAI Presenteeism-13.76 ± 23.299-6.91 ± 20.332
Work Productivity-13.33 ± 24.053-6.80 ± 21.526
WPAI Activity Impairment-15.20 ± 25.466-9.69 ± 23.855
SecondaryChange From Baseline in the European Quality of Life 5D-5L (EQ-5D-5L) Utility Scores and Its Subcomponents up to 16

The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. Change from Baseline in 5-level EuroQol 5-dimension (EQ-5D-5L) Utility Scores. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.

Time frame:
Baseline and week 4 and 16
Reported as:
Mean · Score on a Scale
Change From Baseline in the European Quality of Life 5D-5L (EQ-5D-5L) Utility Scores and Its Subcomponents up to 16
Score on a ScalePlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Utility Score (Week 4)0.1006 ± 0.194700.0694 ± 0.19282
Utility Score (Week 16)0.1630 ± 0.236960.0721 ± 0.23083
Mobility (Week 4)-0.3 ± 0.77-0.3 ± 0.80
Mobility (Week 16)-0.5 ± 0.88-0.3 ± 0.92
Self-Care (Week 4)-0.3 ± 0.81-0.2 ± 0.78
Self-Care (Week 16)-0.5 ± 0.90-0.1 ± 0.86
Usual Activities (Week 4)-0.3 ± 0.83-0.3 ± 0.71
Usual Activities (Week 16)-0.5 ± 0.92-0.3 ± 0.78
Pain/Discomfort (Week 4)-0.4 ± 0.77-0.3 ± 0.81
Pain/Discomfort (Week 16)-0.6 ± 0.93-0.3 ± 0.92
Anxiety/Depression (Week 4)-0.2 ± 0.74-0.1 ± 0.79
Anxiety/Depression (Week 16)-0.3 ± 0.84-0.1 ± 0.91
SecondaryChange From Baseline in Patient-Reported Outcome Measures Information System (PROMIS) Sleep Disturbance up to Week 16

The Patient-Reported Outcome Measures Information System Sleep Disturbance assess self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This includes perceived difficulties and concerns with getting to sleep or staying asleep, as well as perceptions of the adequacy of and satisfaction with sleep. The items are evaluated on a 5-point Likert scale ranging from 1 = "not at all" to 5 = "very much" with a 7-day recall period. Higher score means more active disease. Change from baseline is defined as value at post-baseline visit. A negative change from baseline indicates an improvement.

Time frame:
Baseline and week 4, 12, and 16
Reported as:
Mean · Score on a Scale
Change From Baseline in Patient-Reported Outcome Measures Information System (PROMIS) Sleep Disturbance up to Week 16
Score on a ScalePlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - Placebo
Week 4-1.48 ± 6.489-1.09 ± 6.413
Week 12-2.46 ± 8.196-0.88 ± 8.177
Week 16-3.15 ± 7.761-1.59 ± 7.645

Adverse events

Collected over All-cause mortality and Adverse events were collected from first dose (Day 1) and up to 30 days after the last dose of treatment in the study (up to approximately 164 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo-Controlled Period - Deucravacitinib 6 mg QD0/336 (0%)6/332 (1.8%)39/332 (11.7%)
Placebo-Controlled Period - Placebo0/334 (0%)8/333 (2.4%)32/333 (9.6%)
Active Treatment Period - Deucravacitinib 6 mg QD0/309 (0%)21/309 (6.8%)68/309 (22%)
Active-Treatment Period - Placebo-Deucravacitinib 6 mg QD0/306 (0%)17/306 (5.6%)67/306 (21.9%)
Most frequent serious events
Showing 10 of 51
Most frequent serious events
EventPlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - PlaceboActive Treatment Period - Deucravacitinib 6 mg QDActive-Treatment Period - Placebo-Deucravacitinib 6 mg QD
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3320/3332/3090/306
Angina unstableCardiac disorders0/3320/3330/3091/306
Atrial fibrillationCardiac disorders0/3321/3330/3091/306
Hiatus herniaGastrointestinal disorders0/3320/3330/3091/306
CholelithiasisHepatobiliary disorders0/3320/3331/3091/306
Drug hypersensitivityImmune system disorders0/3320/3330/3091/306
COVID-19 pneumoniaInfections and infestations0/3320/3330/3091/306
Hepatitis infectious mononucleosisInfections and infestations0/3320/3330/3091/306
Herpes zoster disseminatedInfections and infestations0/3320/3330/3091/306
Oral candidiasisInfections and infestations0/3320/3330/3091/306
Most frequent other events
Most frequent other events
EventPlacebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - PlaceboActive Treatment Period - Deucravacitinib 6 mg QDActive-Treatment Period - Placebo-Deucravacitinib 6 mg QD
Upper respiratory tract infectionInfections and infestations17/33210/33332/30933/306
NasopharyngitisInfections and infestations13/33212/33324/30926/306
HypertensionVascular disorders10/33210/33318/30914/306

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - PlaceboTotal
Mean51.7 ± 12.5252.3 ± 12.3252.0 ± 12.41
Sex: Female, Male
Sex: Female, Male(Participants)Placebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - PlaceboTotal
Female164170334
Male172164336
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - PlaceboTotal
Hispanic or Latino10194195
Not Hispanic or Latino165165330
Unknown or Not Reported7075145
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo-Controlled Period - Deucravacitinib 6 mg QDPlacebo-Controlled Period - PlaceboTotal
WHITE263279542
BLACK OR AFRICAN AMERICAN415
AMERICAN INDIAN OR ALASKA NATIVE171936
OTHER272148
CHINESE241438
ASIAN OTHER101
08

Study locations

183 sites
  • Local Institution - 0197
    Gilbert, Arizona 85297, United States
  • Local Institution - 0188
    Jonesboro, Arkansas 72401, United States
  • Local Institution - 0168
    Fontana, California 92335, United States
  • Local Institution - 0199
    Fullerton, California 92835, United States
  • Local Institution - 0038
    Sacramento, California 95815, United States
  • Cohen Medical Centers
    Thousand Oaks, California 91360, United States
  • Local Institution - 0170
    Denver, Colorado 80230, United States
  • Local Institution - 0195
    Clearwater, Florida 33765, United States
  • Local Institution - 0272
    Margate, Florida 33063, United States
  • Local Institution - 0082
    Miami Lakes, Florida 33014, United States
  • Local Institution - 0171
    Gainesville, Georgia 30501, United States
  • Local Institution - 0087
    Boise, Idaho 83702, United States
  • Local Institution - 0080
    Chicago, Illinois 60640, United States
  • Local Institution - 0177
    Orland Park, Illinois 60467, United States
  • Local Institution - 0178
    Schaumburg, Illinois 60195, United States
  • Local Institution - 0083
    Lexington, Kentucky 40504, United States
  • Local Institution - 0042
    Hagerstown, Maryland 21740, United States
  • Local Institution - 0198
    Detroit, Michigan 48202, United States
  • Local Institution - 0201
    Springfield, Missouri 65807, United States
  • Local Institution - 0268
    Kalispell, Montana 59901, United States
  • Local Institution - 0186
    Voorhees Township, New Jersey 08043, United States
  • University Hospitals Cleveland Medical Center-Dermatology
    Cleveland, Ohio 44106, United States
  • Local Institution - 0028
    Middleburg Heights, Ohio 44130, United States
  • Local Institution - 0179
    Perrysburg, Ohio 43551, United States
  • Local Institution - 0182
    Oklahoma City, Oklahoma 73102, United States
  • Local Institution - 0185
    Corvallis, Oregon 97330, United States
  • Local Institution - 0175
    Greenville, South Carolina 29601, United States
  • Local Institution - 0036
    Jackson, Tennessee 38305, United States
  • Local Institution - 0172
    Allen, Texas 75013, United States
  • Local Institution - 0189
    Amarillo, Texas 79124, United States
  • Local Institution - 0032
    Dallas, Texas 75231, United States
  • Local Institution - 0273
    Bothell, Washington 98021, United States
  • Local Institution - 0181
    Beckley, West Virginia 25801, United States
  • Local Institution - 0213
    Ciudad Autónoma de Buenos Aires, Buenos Aires 1111, Argentina
  • Local Institution - 0054
    La Plata, Buenos Aires 1900, Argentina
  • Local Institution - 0215
    Quilmes, Buenos Aires 1878, Argentina
  • Local Institution - 0046
    Córdoba, Córdoba Province X5004CDT, Argentina
  • Local Institution - 0196
    Rosario, Santa Fe Province S2000, Argentina
  • Local Institution - 0047
    San Miguel de Tucumán, Tucumán Province 4000, Argentina
  • Local Institution - 0194
    Buenos Aires, 1426, Argentina
  • Local Institution - 0169
    Buenos Aires, 1428, Argentina
  • Local Institution - 0192
    Buenos Aires, C1427CCL, Argentina
  • Local Institution - 0193
    Mendoza, 5500, Argentina
  • Local Institution - 0220
    Phillip, Australian Capital Territory 2606, Australia
  • Local Institution - 0137
    Botany, New South Wales 2019, Australia
  • Local Institution - 0133
    Westmead, New South Wales 2145, Australia
  • Local Institution - 0132
    Woolloongabba, Queensland 4102, Australia
  • Local Institution - 0211
    Hobart, Tasmania 7000, Australia
  • Local Institution - 0136
    Camberwell, Victoria 3142, Australia
  • Local Institution - 0109
    Vitória, Espírito Santo 29055450, Brazil
  • Local Institution - 0001
    Salvador, Estado de Bahia 40150-150, Brazil
  • Local Institution - 0002
    Juiz de Fora, Minas Gerais 36010-570, Brazil
  • Local Institution - 0219
    Curitiba, Paraná 80030110, Brazil
  • Local Institution - 0214
    Curitiba, Paraná 80440-080, Brazil
  • Local Institution - 0005
    Porto Alegre, Rio Grande do Sul 90480-000, Brazil
  • Local Institution - 0108
    Santo André, São Paulo 09060-870, Brazil
  • Local Institution - 0255
    Plovdiv, Plovdiv 4002, Bulgaria
  • Local Institution - 0248
    Sofia, Sofia (stolitsa) 1463, Bulgaria
  • Local Institution - 0253
    Burgas, 8000, Bulgaria
  • Local Institution - 0249
    Plovdiv, 4000, Bulgaria
  • Local Institution - 0267
    Plovdiv, 4000, Bulgaria
  • Local Institution - 0246
    Plovdiv, 4001, Bulgaria
  • Local Institution - 0247
    Plovdiv, 4001, Bulgaria
  • Local Institution - 0245
    Sofia, 1505, Bulgaria
  • Local Institution - 0259
    Sofia, 1784, Bulgaria
  • Local Institution - 0250
    Varna, 9000, Bulgaria
  • Local Institution - 0226
    Santiago, Santiago Metropolitan 0, Chile
  • Local Institution - 0099
    Santiago, Santiago Metropolitan 7500571, Chile
  • Local Institution - 0073
    Santiago, Santiago Metropolitan 7501126, Chile
  • Local Institution - 0222
    Santiago, Santiago Metropolitan 7510047, Chile
  • Local Institution - 0111
    Santiago, Santiago Metropolitan 7640881, Chile
  • Local Institution - 0261
    Viña del Mar, Valparaiso 2531172, Chile
  • Local Institution - 0149
    Hefei, Anhui 230071, China
  • Local Institution - 0159
    Beijing, Beijing Municipality 100005, China
  • Local Institution - 0190
    Chongqing, Chongqing Municipality 400010, China
  • Local Institution - 0147
    Guangzhou, Guangdong 510120, China
  • Local Institution - 0143
    Shenzhen, Guangdong 518020, China
  • Local Institution - 0150
    Dalian, Liaoning 116000, China
  • Local Institution - 0146
    Shanghai, Shanghai Municipality 200040, China
  • Local Institution - 0145
    Yiwu, Zhejiang 322000, China
  • Local Institution - 0071
    Bucaramanga, Santander Department 680003, Colombia
  • Local Institution - 0072
    Barranquilla, 080020, Colombia
  • Local Institution - 0069
    Bogotá, 110221, Colombia
  • Local Institution - 0063
    Bogotá, 111156, Colombia
  • Local Institution - 0070
    Cali, 760042, Colombia
  • Local Institution - 0094
    Medellín, 050021, Colombia
  • Local Institution - 0064
    Medellín, 050034, Colombia
  • Local Institution - 0065
    Zipaquirá, 250252, Colombia
  • Local Institution - 0225
    Prague, Praha 5 150 06, Czechia
  • Local Institution - 0269
    Uherské Hradiště, Zlín 68601, Czechia
  • Local Institution - 0202
    Zlín, Zlín 760 01, Czechia
  • Local Institution - 0018
    Ostrava, 722 00, Czechia
  • Local Institution - 0208
    Pardubice, 530 02, Czechia
  • Local Institution - 0097
    Prague, 12850, Czechia
  • Local Institution - 0017
    Prague, 130 00, Czechia
  • Local Institution - 0013
    Helsinki, 00290, Finland
  • Local Institution - 0089
    Kuopio, 70100, Finland
  • Local Institution - 0119
    Turku, FI-20521, Finland
  • Local Institution - 0077
    Chambray-lès-Tours, 37170, France
  • Local Institution - 0075
    Montpellier, 34295, France

Showing the first 100 of 183 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Oct 2024, 38 months.

Results were first posted in Oct 2025, 1 year after primary completion.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 38 months is above that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2024 → Oct 2024, on Oct 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2021
First posted
Jun 1, 2021
StartActual
Jul 13, 2021
Primary completionActual
Oct 10, 2024was Sep 2024
CompletionEst.
Jun 3, 2027
Results first posted
Oct 24, 2025
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 5, 2024→Oct 10, 2024
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Primary completion Sep 5, 2024→Oct 10, 2024
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04908202
Responsible party
Sponsor
First posted
Jun 1, 2021
Start date
Jul 13, 2021
Primary completion
Oct 10, 2024
Completion
Jun 3, 2027 (estimated)
Results posted
Oct 24, 2025
Last update
Oct 16, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion